Versartis' Series D Round

Versartis raised a round of funding on October 08, 2013.

Versartis is a biotechnology company developing therapeutics for the treatment of endocrine disorders. The company's lead product candidate is VRS-317, a once monthly form of human growth hormone. Ver…

Articles about Versartis' Series D Round: